# This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

> **NCT01035255** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 8442 (actual)

## Conditions studied

- Heart Failure With Reduced Ejection Fraction

## Interventions

- **DRUG:** LCZ696 200 mg BID
- **DRUG:** Enalapril 10 mg BID

## Key facts

- **NCT ID:** NCT01035255
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-12
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 8442 (ACTUAL)
- **Why stopped:** Early termination was approved due to compelling efficacy of LCZ696 in patients with HF \& reduced EF after final pre-specified interim analysis 28-Mar-2014.
- **Last updated:** 2016-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01035255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01035255, "This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01035255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*